DFS at 24 months improved from 79% with observation to 96% with the use of a 14-gene assay to guide decision making about ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

The U.S. FDA has paused Rocket Pharmaceuticals' mid-stage gene therapy trial after a patient died from serious complications, ...

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy ...

A team of scientists from the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy, has identified a ...

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) has announced pivotal progress in its TSHA-102 gene therapy program for Rett ...

A team of scientists from the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy, has identified a ...

While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of ...

A personalized gene editing therapy was successfully used to treat an infant with CPS1 deficiency, a disease that causes ...

Find out if gene therapy has also find its way into skin diseases. With two approvals in the last 2 years, is it the start of ...